[go: up one dir, main page]

WO2008110570A1 - Procédé pour étudier la prolifération de cellules progénitrices endothéliales et l'influence potentielle de composés sur leur comportement de prolifération - Google Patents

Procédé pour étudier la prolifération de cellules progénitrices endothéliales et l'influence potentielle de composés sur leur comportement de prolifération Download PDF

Info

Publication number
WO2008110570A1
WO2008110570A1 PCT/EP2008/052933 EP2008052933W WO2008110570A1 WO 2008110570 A1 WO2008110570 A1 WO 2008110570A1 EP 2008052933 W EP2008052933 W EP 2008052933W WO 2008110570 A1 WO2008110570 A1 WO 2008110570A1
Authority
WO
WIPO (PCT)
Prior art keywords
cells
cfu
medium
epc
egm
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/052933
Other languages
English (en)
Inventor
Dirk Strunk
Eva Rohde
Christina Bartmann
Katharina Schallmoser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medizinische Universitaet Graz
Original Assignee
Medizinische Universitaet Graz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universitaet Graz filed Critical Medizinische Universitaet Graz
Publication of WO2008110570A1 publication Critical patent/WO2008110570A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/165—Vascular endothelial growth factor [VEGF]

Definitions

  • the present invention provides a method for determining the colony forming units (CFU) of endothelial progenitor cells (EPC).
  • CFU colony forming units
  • EPC endothelial progenitor cells
  • the present invention also provides a method for analyzing said influence by comparing the CFU of EPC under conditions exposed to test compounds and control conditions. This also comprises the analysis of the influence of different conditions on the CFU of EPC by comparison to standard conditions.
  • the present invention further provides a specific medium for culturing endothelial cells.
  • Colony assay methods have been widely used for studying progenitor cell presence in hematopoietic tissues.
  • the assessed progenitor cells are not necessarily of hematopoietic origin, because a large variety of cells is present in the hematopoietic tissues of the bone marrow, the thymus and the spleen. This comprises erythrocytes and leucocytes as types of hematopoietic cells (and the related mast cells), but also fat cells, fibroblasts and endothelial cells as well as their corresponding progenitor cells, which are able to form macroscopic colonies and are therefore also generally called colony- forming cells (CFC).
  • CFC colony- forming cells
  • Fibroblast precursors existing within the hematopoietic system also have been evaluated with a colony assays method (CFU-F), introduced by Friedenstein in 1974 (Friedenstein A. et al. (1974) Exp. Hematol. 2(2): 83-92).
  • CFU-F colony assays method
  • CFC assays for hematopoietic cells are routinely used standard tests to determine the functional capacity and quality of hematopoietic stem cells (HSC) in the case of clinical HSC transplantation.
  • HSC hematopoietic stem cells
  • LTC-IC initiating cells
  • LTC-IC longterm culturing of initiating cells derived from human bone marrow enables researchers to investigate these very primitive HSC (Petzer et al. (1996) J. Exp. Med. 183(6): 2551-2558).
  • endothelial cells (EC) and endothelial progenitor cells (EPC) are among hematopoietic cells, fat cells and fibroblasts (and the related mast cells) also known to reside in the hematopoietc tissues.
  • EPC are characterized on a phenotypical and morphological level to a rather good extent. For example, it has been shown that statins induce EPC differentiation from mononuclear cells and therefore lead to an increase in total numbers of EPC (Dimmeler et al. (2001) J. Clin. Invest. 108(3): 391-397).
  • a subset of circulating human cells expressing the surface marker CD34 was shown to also express VEGFR-2 and AC133.
  • Those CD34 + , VEGFR-2 + and AC133 + circulating cells seem to represent functional endothelial precursor cells which may play a role in neo-angiogenesis (Peichev M. et al. (2000) Blood 95(3): 952-958).
  • MGF-EGFP supernatant with a titer of 0.5-1 x 10 6 infectious units/ml is needed for the transduction of the EPC.
  • appropriate cells are trans fected with a retroviral vector, which contains the coding sequence for EGFP under the control of the Moloney murine leukemia long terminal repeat. Viral supernatant produced by those cells is then assayed for its infectious titer after two to three days of incubation.
  • the EPC are then infected with this retrovirus containing supernatant for four hours on two consecutive days.
  • the cells are in a further step sorted by fluorescence cytometry using the expression of exogenous EGFP and, with the help of a cell sorter, cells positive for EGFP expression are in the next step placed as single cells in the wells of a precoated 96-well tissue culture plate. Individual cells are examined under a fluorescence microscope to ensure that only one cell has been placed into each well. After 14 days of incubation, the colony growth is scored and large colonies are further subcultured for another seven days and, if they still show growth after this incubation period, again subcultured for another seven days. EPC with high proliferative potential (HPP) are defined as large colonies that form secondary and tertiary colonies after replating as described.
  • HPP high proliferative potential
  • the assay for analysis of the proliferation of EPC described above uses a rather time-consuming and elaborate protocol. It is for example necessary to provide retrovirus containing supernatant to infect the cells with vector coding for EGFP. EPC analyzed following this protocol are therefore always modified in such a way, that they contain retroviral DNA and express exogenous EGFP for identification and sorting reasons. Furthermore, technical equipment like a FACS machine coupled to a cell sorter and a fluorescence microscope are required to proceed according to the protocol. Of course, persons using this assay to determine the CFU of EPC need to be experienced with the technical equipment just mentioned. Therefore, there is a need for a simple method, which is easy to handle and can be used by a person not necessarily having a strong background in instrumental setups. The method should furthermore be as cheap as possible and adapted for a rapid determination of the proliferation of EPC.
  • CFU colony forming units
  • EPC endothelial progenitor cells
  • CFU colony forming unit
  • EPC endothelial progenitor cells
  • a method of determining the colony forming units (CFU) of endothelial progenitor cells (EPC) comprising the following steps: a) Seeding starter cells in an appropriate medium at such a density, that contact inhibition cannot take place; b) Incubating cells for several days; and c) Identifying colonies.
  • a method of identifying compounds and/or conditions exerting an effect on the CFU of EPC comprising the following steps: a) Seeding starter cells in an appropriate medium at such a density, that contact inhibition cannot take place; b) Contacting cells with one or several test compound(s) and/or test conditions; c) Incubating cells for several days; d) Identifying colonies; and e) Comparing with a control.
  • colonies are identified by staining of the colonies and/or counting of the colonies.
  • starter cells comprise human umbilical vein endothelial cells (HUVEC, commercially available from Cambrex, USA), human microvascular vein endothelial cells (HMVEC, commercially available from Cambrex, USA),endothelial cells prepared from umbilical cord blood (UCB-EC, preparation according to example 1) and EPC derived from any mammalian solid organ or vasculature such as the bone marrow or the lung.
  • HMVEC human umbilical vein endothelial cells
  • HMVEC human microvascular vein endothelial cells
  • UMB-EC preparation according to example 1
  • EPC EPC derived from any mammalian solid organ or vasculature such as the bone marrow or the lung.
  • native, not modified starter cells are used.
  • cells are used, which express exogenous protein(s) excluding any protein which can be used as marker for identification and sorting purposes.
  • the medium chosen for culturing of the cells comprises EGM-2, hydrocortisone, VEGF, ascorbic acid and heparin and is supplemented with FBS.
  • the medium chosen for culturing of the cells comprises EGM-2, hydrocortisone, VEGF, ascorbic acid and heparin and is supplemented with human platelet lysate (HPL, prepared from platelet rich plasma) instead of FBS.
  • the medium chosen for culturing of the cells comprises EGM-2, hydrocortisone, VEGF, ascorbic acid and heparin, is supplemented with FBS or HPL and additionally comprises small amounts of FBS.
  • the medium chosen for culturing of the cells comprises EGM-2, hydrocortisone, VEGF, ascorbic acid, heparin and small amounts of FBS, is supplemented with FBS or HPL and also comprises VEGF, human fibroblast growth factor B and the R3 -insulin like growth factor 1.
  • the cells are seeded at a density of 1 cell/cm 2 in a 150 cm 2 or a 55 cm 2 culture dish to ensure, that the cells are proliferating without any contact inhibition.
  • the cells are incubated for 12 days with a medium change every third day.
  • the cells and colonies are stained with Harris" Hematoxylin staining.
  • a colony contains more than 50 cells and is defined according to its size as derived from a regular CFU or a CFU with high proliferative potential (HPP).
  • HPP high proliferative potential
  • a control is defined as an assay under identical conditions, wherein the appropriate medium does not contain one or several test compound(s) or an assay under standard conditions.
  • a test compound/condition is defined as a positive regulator of the CFU-EPC when it is increasing the number of CFU compared to a control.
  • a test compound/condition is defined as a negative regulator of the CFU-EPC when it is decreasing the number of CFU compared to a control.
  • test compound or compounds is/are selected from the group of test compounds comprising small molecules derived from small molecule libraries, growth factors and compounds of pharmaceutical interest.
  • a cell culture medium which comprises EGM-2, hydrocortisone, VEGF, ascorbic acid and heparin and is supplemented with HPL.
  • a cell culture medium which comprises EGM-2, hydrocortisone, VEGF, ascorbic acid, heparin, small amounts of FBS and is supplemented with HPL.
  • the provided cell culture medium is used to culture endothelial cells.
  • Fig. IA shows early outgrowth of endothelial cells in primary culture from umbilical cord blood (UCB-EC) after five days of culture.
  • Fig. IB shows a confluent cobblestone-like monolayer of late outgrowth UCB-EC at passage 3 and 23 days of culture.
  • Fig. 2 depicts phenotypic FACS-profiling of UCB-EC, HUVEC an HMVEC analyzing the expression of CD31, CD90, CD 13, CD29, CD73, CD 105, CD 146, HLA-AB and HLA-DR as well as binding of BS-I lectin.
  • Fig. 3 shows colonies of CFU-EPC assays using UCB-EPC (passage 4). The photographs were taken after 12 days of incubation. UCB-EPC depicted on the left side were incubated with HPL EGM-2 medium (see appendix), whereas the UCB-EC depicted on the right side were incubated with conventional EGM-2 medium (supplemented with FBS instead of HPL, see appendix).
  • Fig. 4 shows the number of total colonies and photographs of culture dishes after staining. The fold increase of cells after an incubation period of 12 days is also indicated.
  • Cells (HUVEC or UCB-EC) were either incubated with HPL EGM-2 medium (marked as HPL, see appendix) or HPL-3 EGM-2 medium, which lacks the growth factors VEGF, human fibroblast growth factor B and the R3-insulin like growth factor 1 (marked as HPL/-3).
  • Fig. 5 depicts the numbers of colonies of various colony sizes as indicated. HUVEC or UBC-EC (each passage 4) incubated either with conventional EGM-2 (marked
  • HPL EGM-2 marked HPL
  • HPL-3 EGM-2 marked HPL/-3 medium were tested in the CFU-EPC assays.
  • Figures 6 - 10 show standardized quantifications using the CFU-EPC assay as described in the present invention with conventional EGM-2 medium. Absolute colony counts (upper diagram), the number of HPP CFU-EPC (middle diagram) and the percentage of HPP CFU-EPC (bottom) are given. Erythropoietin (EPO) was added to the medium in the amounts indicated underneath the bars. The following cells were used for the assay: Fig. 6: HUVEC (passage 3) Fig. 7: HMVEC (passage 2)
  • Fig. 8 UCB-EC (passage 3)
  • Fig. 9 UCB-EC (passage 4)
  • Fig. 10 UCB-EC (passage 5)
  • CFU colony forming units
  • proliferation of cells is intended to mean the multiplication of cells thereby leading to an increase in the cell number.
  • the proliferation of cells may be detected by any suitable method. The easiest way to measure proliferation is to seed the cells in a specific, predetermined density and to count the cell number at different time points after seeding.
  • Another way of measuring the proliferation of cells is a [ 3 H] -thymidine incorporation assay which involves the addition of [ 3 H] -thymidine to the cells, incubating them for a specific time, lysing the cells and counting the incorporation in a scintillation counter.
  • kits like the tetrazolium assay (MTT, Sigma) may also be used for measuring proliferation.
  • a "colony” is defined as consisting of preferably at least 200, more preferably of at least 100 and most preferably of at least 50 cells after incubation and proliferation of the single CFU. This is dependent on the size of the endothelial cells used in the assay.
  • a colony is defined as consisting of at least 50 cells for the following cells: HUVEC (human umbilical vein endothelial cells, commercially available from Cambrex, USA), HMVEC (human microvascular vein endothelial cells, commercially available from Cambrex, USA) and endothelial cells prepared from umbilical cord blood (UCB-EC, preparation according to example 1.
  • Progenitor cells are early descendants of stem cells which may lose their ability of self-renewal.
  • the progenitor cells are able to differentiate to different cell types within one germ layer, but in contrast to stem cells they cannot differentiate to cells of a different germ layer.
  • the endoderm is the internal cell layer of the embryo from which the lung, digestive tract, bladder and urethra are formed.
  • the ectoderm is the surface layer of the embryo that develops into the epidermis, skin, nerves, hair, etc.
  • the mesoderm is the middle cell layer of the embryo from which the connective tissue, muscles, cartilage, bone, lymphoid tissues, etc. are formed.
  • the progenitor cells used are preferably endothelial progenitor cells from different cell preparations, most preferably UCB- EC, HUVEC and HMVEC. It is also preferred to use endothelial progenitor cells derived from any mammalian solid organ or vasculature, most preferably cells derived from the bone marrow or the lung.
  • the term "cell culture” refers to the maintenance and propagation of cells and preferably animal (including human-derived cells) in vitro.
  • the cells may include progenitor cells as defined above.
  • the cells are either used in a native, non modified way or are modified in such a way, that the expression of proteins, which can be used as markers for identification and sorting purposes is excluded.
  • native cells means that the cells are not manipulated by any method to either express any exogenous gene or to contain exogenous DNA or RNA or the like, which may in any way influence the regulation of gene expression in the cells.
  • the cells may be transduced or transfected with DNA or RNA or manipulated in any other way, which may lead to expression of exogenous genes or silencing of endogenous genes or to any other effect on the regulation of gene expression, as long as the cells are not manipulated in such a way, that they express any protein, which is suitable as marker for the identification and sorting of cells using for example a FACS machine.
  • This comprises for example GFP, EGFP, YFP, CFP and so on.
  • the cells are seeded in cell culture dishes at such a density, that contact inhibition cannot take place.
  • contact inhibition means, that cells inhibit their cell divisions and therefore stop growing if they are in too dense proximity to each other.
  • An area of 1 cm 2 per cell as used in the methods of the present invention is by far enough to exclude this phenomenon arising during proliferation.
  • seeding endothelial cells at a density of 1 cell / cm 2 is the most preferred density of seeding the cells according to the present invention without the occurrence of contact inhibition.
  • a density of 2 to 10 cells / cm 2 is also preferred.
  • the most preferred embodiment for culturing the cells is in any standard incubator suitable for growing cell culture cells, wherein cells are cultured at 37°C in 5% CO 2 in humidified atmosphere, also referred to as standard conditions known to the skilled person in the art in contrast to any test conditions.
  • colonies can be identified by staining and/or counting of cells.
  • Cells grown on a cell culture dish can be stained according to the methods of the present invention by any known and suitable protocol. This comprises staining of the cells for example with Harris Hematoxylin staining or tryptophan blue-solution with staining by Harris Hematoxylin being the most preferred way. If required, the cells must be fixed prior to staining, for example by cold Aceton/Methanol as described in the example section.
  • Directly identified or stained cells/colonies can be counted and colony sizes measured by visual inspection or with an analyzer and the corresponding software or by any other method suitable for determining the number of cells/colonies and the sizes of colonies.
  • a standard automatic analyzer for example the use of a ChemiDocTM XRS Universal Hood II or an AID BacSpotTM System.
  • Test compounds which can be added to the medium according to one embodiment of the present invention for determining a possible effect on the proliferation of endothelial progenitor cells can be selected from a large variety of molecules. This comprises molecules derived from libraries of small molecules, pharmaceuticals, molecules isolated from or derived from tissues like growth factors and so on. Most preferred compounds are neutralizing antibodies against growth factors or any other potential therapeutically active antibodies.
  • Test Conditions are conditions, which differ in any aspect from the standard conditions known to the person skilled in the art as defined above . Because the differing parameter(s) is/are known, it is possible to evaluate the influence of the specific parameter(s) by comparing the results to results obtained under standard conditions.
  • Cell culture medium (“medium”) is used for the maintenance of cells in culture in vitro. For some cell types, the medium may also be sufficient to support the proliferation of the cells in culture.
  • a medium according to the present invention provides nutrients such as energy sources, amino acids and anorganic ions. Additionally, it may contain a dye like phenol red, sodium pyruvate, several vitamins, free fatty acids and trace elements.
  • a preferred medium is a medium suitable for culturing endothelial cells (for example EGM-2 [endothelial cell medium] commercially available from Cambrex, USA).
  • the term "cell culture medium supplement” within the meaning of the present invention refers to a medium additive which is added to the medium to stimulate the proliferation of the cells. Usually this supplement will contain one or more growth factors which are responsible for the stimulation of proliferation.
  • FBS foetal bovine serum
  • HPL human platelet lysate
  • HPL is used as cell culture medium supplement, it is preferred to use plasma- free HPL which is prepared according to a method comprising the following steps: a) preparing platelet-rich plasma; b) removing the plasma; and c) lysing the platelets.
  • recombinant albumin may be added to the culture supplement.
  • supply is not intended to comprise medium additives which are added to the medium for the purpose of freezing the cells.
  • hormones such as hydrocortisone, antioxidizing agents such as ascorbic acid, antibiotics such as gentamycin and antifungal substances such as amphotericin, which all may be added.
  • hormones such as hydrocortisone, antioxidizing agents such as ascorbic acid, antibiotics such as gentamycin and antifungal substances such as amphotericin, which all may be added.
  • Heparin may also be additionally added to the medium to increase the uptake of certain growth factors such as VEGF.
  • growth factor is intended to comprise proteins which stimulate proliferation of cells by binding to a specific receptor. Usually, growth factors only act on specific cell types which express the respective receptor. Examples of growth factors are epidermal growth factor (EGF), nerve growth factor (NGF), platelet derived growth factor (PDGF), fibroblast growth factor B (FGF), vascular endothelial growth factor (VEGF), bone morphogenetic proteins (BMP), colony stimulating factors (CSF), R3-insulin like growth factor 1 etc.
  • EGF epidermal growth factor
  • NGF nerve growth factor
  • PDGF platelet derived growth factor
  • FGF fibroblast growth factor B
  • VEGF vascular endothelial growth factor
  • BMP bone morphogenetic proteins
  • CSF colony stimulating factors
  • Medium comprises cell culture medium as defined above, preferably EGM-2 (commercially available from Cambrex, USA). Further additives added to the medium typically comprise at least hydrocortisone, VEGF, EGF, FGF, R3-insulin like growth factor 1 and heparin. Additional compounds which can be further added to the medium comprise antioxidants, antibiotics and anti- fungal agents.
  • EGM-2 commercially available from Cambrex, USA.
  • Further additives added to the medium typically comprise at least hydrocortisone, VEGF, EGF, FGF, R3-insulin like growth factor 1 and heparin. Additional compounds which can be further added to the medium comprise antioxidants, antibiotics and anti- fungal agents.
  • a medium which can be used in the methods of the invention seems to require at least EGM-2, VEGF, hydrocortisone and FBS or HPL as supplement.
  • the additional minimal additives comprise at least hydrocortisone, 2% FBS, VEGF, EGF, FGF and R3-insulin like growth factor 1 or alternatively the minimal additional additives comprise at least hydrocortisone and VEGF.
  • either FBS is added to the medium to a final concentration of approximately 1-20% v/v, preferably of approximately 5-18% v/v, more preferably of approximately 8-12% v/v and most preferably of approximately 10% v/v.
  • HPL instead of FBS is added to the medium to a final concentration of approximately 1 - 15 % v/v, preferably o f approximately 4-11% v/v, more preferably of approximately 6-9% v/v and most preferably of approximately 7,0% v/v.
  • HPL is preferably a plasma- free HPL.
  • the medium will additionally comprise an antioxidizing agent such as ascorbic acid, an antibiotic agent such as gentamycin, an antifungal agent such as amphotericin and an agent increasing the uptake of certain growth factors such as heparin.
  • an antioxidizing agent such as ascorbic acid
  • an antibiotic agent such as gentamycin
  • an antifungal agent such as amphotericin
  • an agent increasing the uptake of certain growth factors such as heparin.
  • a suitable cell culture medium is comprised of EGM-2, hydrocortisone, optionally 2% FBS, VEGF, ascorbic acid, heparin, gentamycin, amphotericin, EGF, FGF and R3 -insulin like growth factor 1 and 10% v/v FBS as supplement.
  • a suitable cell culture medium is comprised of EGM- 2, hydrocortisone, optionally 2% FBS, VEGF, ascorbic acid, heparin, gentamycin, amphotericin, EGF, FGF and R3-insulin like growth factor 1 and 2% v/v FBS as supplement.
  • Yet another particularly suitable medium according to the methods of the present invention is medium comprised of EGM-2, hydrocortisone, optionally 2% FBS, VEGF, ascorbic acid, heparin, gentamycin, amphotericin, EGF, FGF and R3-insulin like growth factor 1 and 7.5% v/v HPL as supplement.
  • One of the most preferred embodiment of the present invention is cell culture medium comprising EGM-2, hydrocortisone, VEGF, ascorbic acid and heparin, supplemented with HPL to a final concentration of approximately 7.5% v/v.
  • such cell culture medium comprises small additional amounts of FBS, most preferably approximately 2%.
  • medium comprising EGM-2, hydrocortisone, VEGF, ascorbic acid, heparin, 7,5% v/v HPL as supplement and, optionally, additionally 2% FBS
  • medium comprising EGM-2, hydrocortisone, optionally 2% FBS, VEGF, ascorbic acid, heparin, gentamycin, amphotericin, EGF, FGF and R3-insulin like growth factor 1 and 10% v/v FBS as supplement.
  • the term "approximately” describes a deviation of the indicated value by at least 10 %, preferably by at least 5 % and most preferably by at least 1 %.
  • HPP-CFU describes CFU of endothelial cells with a high proliferative potential. This means in the context of the present invention, that there are some CFU among the total CFU, which exhibit a particular high proliferative rate and are thus forming colonies of larger size.
  • larger size implicates a reference size of a colony, which is defined according to the present invention depending on the cell culture medium, which is used for culturing of the cells.
  • a HPP-CFU is defined as having a colony size larger than 2.0 mm if a medium comprising EGM-2, hydrocortisone, VEGF, EGF, FGF, the R3-insulin like growth factor 1 containing FBS as supplement or medium comprising EGM-2, hydrocortisone, VEGF containing HPL as supplement and lacking the three growth factors VEGF, FGF and the R3 -insulin like growth factor 1 is used.
  • a HPP-CFU is defined in an alternative CFU- EPC assay, which is also preferred, as having a colony size larger than 4.0 mm.
  • a regular CFU is defined as having a colony size smaller than or equivalent to the sizes just mentioned (either smaller than or equivalent to 2.0 mm resp. 4.0 mm).
  • test compound(s) and/or test conditions can be determined according to one method of the present invention.
  • the CFU-EPC need to be compared to a suitable control.
  • the influence of test conditions as described above can be analyzed by the comparison to standard conditions mentioned above.
  • suitable control in this context means, that an assay under identical conditions but without adding one or several test compound(s) to the medium is performed in parallel to the assay, wherein the cells are exposed to one or several compound(s).
  • in parallel refers to the whole protocol of the assay including sizes of cell culture dishes, incubation times and media changes.
  • one or several test compound(s) and/or test conditions might have a positive or negative influence on the CFU-EPC. If the addition of one or several test compound(s) and/or test conditions leads to a significant increase in the numbers of CFU-EPC, the compound(s)/conditions show(s) a positive effect on the proliferation of EPC in vitro. Accordingly, the addition of one or several test compound(s)/certain conditions leading to a significant decrease in the numbers of CFU-EPC, the compound(s) show(s) a negative effect on the proliferation of EPC in vitro.
  • test compound increases the CFU-EPC numbers by at least 3%, at least 5% or at least 10%.
  • the number is increased by at least 25%, 50% or 75%. More preferably, the number of CFU-EPC is increased by a factor of at least 2, 5 or 10.
  • a significant decrease according to the present invention means that the test compound reduces the CFU-EPC numbers by at least 3%, at least 5% or at least 10%. Preferably, the number is reduced by at least 15%, by at least 25% or at least 50%. More preferably, the number of CFU-EPC is reduced by at least 75%, 80% or 95%.
  • the present invention provides a cheap, simple and rapid alternative method for determining the CFU of EPC as well as a method for determining a potential effect of one or several test compound(s) and/or test conditions on the proliferation behaviour of EPC. Furthermore, the invention is based on the surprising finding that EGM-2 cell culture medium with hydrocortisone, VEGF, ascorbic acid, heparin and HPL as supplement but lacking the three growth factors EGF, FGF and R3-insulin like growth factor 1 , can be used as an alternative to the same cell culture medium, but comprising FBS as supplement and the three growth factors mentioned above for culturing endothelial cells.
  • Example 1 Preparation of test endothelial cells derived from umbilical cord blood (UCB-EC)
  • EPC endothelial precursor cells
  • Example 2 the cells were characterized (example 2) and the method of the present invention (example 3) was used to determine the colony forming units (CFU) of the UCB-EPC.
  • CFU colony forming units
  • umbilical cord blood (UCB)-derived EC were generated by culturing UCB-mononuclear cells according to previously published methods (Ingram D. et al. (2004) Blood 104(9):2752-2760).
  • cord blood was collected in 50 ml vials containing 5000 LU. heparin.
  • mononuclear cells were seeded into coated six-well plates in conventional EGM-2 medium (see appendix) at a density of 1-3x10 7 /cm 2 .
  • Cells were cultured at 37°C in 5% CO 2 in humidified atmosphere and medium change was performed daily for seven days and afterwards every second day.
  • Example 2 Multiparameter flow cytometry to analyze surface markers of UCB- EC, HMVEC and HUVEC
  • the surface marker expression of EC was analyzed with a four colour FACS-Calibur instrument equipped with a 488 nm argon ion laser and a 635 nm red diode laser (Becton Dickinson). After trypsinizing, cells were washed, blocked with sheep serum and labelled for 25 minutes at 4°C at concentrations according to individual titration with BS-I lectin and monoclonal antibodies against HLA-AB (Harlan Sera-Lab), HLA-DR, CD13, CD14, CD29, CD31, CD45, CD56, CD73(BD), CD90, CD105 (Caltag Laboratories), CDl 17, CD123, CD133 (Miltenyi) and CD146 (clone P1H12, Chemicon).
  • FIG. 2 indicates that all three cell lines express or lack the same surface markers. The markers show a distribution typical for endothelial cells and it was therefore confirmed, that all three cell lines used in the tests of the following examples were indeed endothelial cells.
  • Example 3 Determination of colony forming units (CFU) of endothelial progenitor cells (EPC) in UCB-EC, HMVEC and HUVEC
  • UCB-EC, HMVEC and HUVEC were thawed and seeded for up to 48 hours at a density of 1000 to 2000 cells/cm 2 in conventional EGM-2 medium (see appendix). Cells were then trypsinized and seeded at a density of 1 cell/cm 2 in 150 cm 2 culture dishes, again in conventional EGM-2 medium. The medium was changed every three days. After 12 days, cells were washed three times with PBS (pH 7.2 -7.3), fixed with cold Aceton/Methanol (3:2 parts v/v, Merck) for 15 minutes, air dried, rehydrated with deionized water for 10 minutes and stained with Harris" Hematoxylin stain (Merck) for 12 minutes.
  • PBS pH 7.2 -7.3
  • Aceton/Methanol 3:2 parts v/v, Merck
  • the numbers of colonies were determined by visual inspection as well as counted using a ChemiDocTM XRS Universal hood II and analysing software or an AID BacSpotTM System with a colony/CFU being defined as consisting of at least 50 cells. Colonies with a size larger than 2.00 mm in diameter were regarded as being derived from EPC with high proliferative potential (HPP) and their number was also counted (so called HPP CFU-EPC). The number of HPP CFU-EPC was expressed as % of all colonies formed by EPC (CFU-EPC).
  • Table 1 shows, that all three cell lines contain EPC capable of forming colonies with HUVEC showing the highest overall number of colonies.
  • UCB-EC of later passages contained the highest % of HPP CFU-EPC among the cells tested.
  • Table 1 result of an experiment performed in triplicates:
  • Example 4 Use of HPL-supplemented medium in comparison to FBS- supplemented medium in the determination of CFU-EPC
  • HPL instead of FBS as supplement in EGM-2 resulted in a strong increase in the numbers as well as the sizes of colonies. Therefore, in case HPL EGM-2 medium was used, colonies with a size larger than 4.00 mm in diameter instead of 2.00 mm were defined as being derived from EPC with high proliferative potential (HPP CFU-EPC, see example 5).
  • Example 5 Influence of certain growth factors in HPL-supplemented medium on the quantity and absolute cell numbers of CFU-EPC
  • UCB-EC and HUVEC were thawed and seeded for about 24 hours at a density of 1000 to 2000 cells/cm 2 either in HPL EGM-2 medium or HPL-3 EGM-2 medium (see appendix). Cells were then trypsinized and seeded at a density of 1 cell/cm 2 in 150 cm 2 culture dishes, again either in HPL EGM-2 medium or HPL-3 EGM-2 medium. The corresponding medium was changed every 3 days.
  • HPL EGM-2 medium The quantity of colonies in both cell types was higher using fully supplemented HPL EGM-2 medium. This correlated with a strong increase of the total cell numbers on plates if HPL EGM-2 medium was used (for HUVEC a 467 fold and for UCB-EC a 604 fold increase) compared to an increase 17 fold in HUVEC and 71 fold in UCB- EC if HPL-3 EGM-2 medium was used (figure 4). However, the cells were growing and colonies were detectable in case HPL EGM-2 medium lacking EGF, FGF and R3-insulin like growth factor 1 was used for culturing. Therefore, those three growth factors can, in principle, be omitted from the medium containing HPL as supplement.
  • Example 6 Comparison of fully supplemented HPL EGM-2 medium, HPL EGM- 2 medium lacking certain growth factors and fully supplemented FBS EGM-2 medium for the use in CFU-EPC assays
  • Passage 4 UCB-EC and passage 4 HUVEC were thawed and seeded for about 12 hours at a density of 1000 to 2000 cells/cm 2 either in conventional EGM-2 medium, HPL EGM-2 medium or HPL-3 EGM-2 medium (see appendix). Cells were then trypsinized and seeded at a density of 1 cell/cm 2 in 150 cm 2 culture dishes, again either in conventional EGM-2 medium, HPL EGM-2 medium or HPL-3 EGM-2 medium. The corresponding medium was changed every three days.
  • EPO represents a test compound, which can be chosen from a large group of compounds with possible influence on the CFU-EPC. This group comprises small molecules from molecule libraries, growth factors and compounds of pharmaceutical interest.
  • Randomised buffy coats from four different ABO- and Rhesus-identical donations and one bag containing plasma from one of the four donors were connected sterilely (TSCD, Terumo Corp., Tokyo, Japan) in series and pooled by gravity in the lowest container.
  • the pooled BCs were centrifuged at 34 Ig at 22°C for 6 minutes and the platelet-rich plasma was leukocyte-depleted by inline filtration (PALL Autostop, Pall, Dreieich, Germany) and transferred into a platelet storage bag (ELX, PALL, Dreieich, Germany).
  • the mean ⁇ SD platelet concentration was 0.93 ⁇ 0.10xl0 9 /ml.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un procédé simple et rapide pour déterminer les unités formant colonie (CFU) de cellules progénitrices endothéliales (EPC). De plus, l'invention concerne un procédé d'identification des composés exerçant un effet sur ces CFU d'EPC. La présente invention concerne également un milieu pour mettre en culture des cellules endothéliales, qui est composé d'EGM-2, d'hydrocortisone et de VEGF, ainsi que d'un lysat de plaquettes humaines (HPL) en tant que supplément.
PCT/EP2008/052933 2007-03-13 2008-03-12 Procédé pour étudier la prolifération de cellules progénitrices endothéliales et l'influence potentielle de composés sur leur comportement de prolifération Ceased WO2008110570A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07104031.5 2007-03-13
EP07104031 2007-03-13

Publications (1)

Publication Number Publication Date
WO2008110570A1 true WO2008110570A1 (fr) 2008-09-18

Family

ID=39272241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/052933 Ceased WO2008110570A1 (fr) 2007-03-13 2008-03-12 Procédé pour étudier la prolifération de cellules progénitrices endothéliales et l'influence potentielle de composés sur leur comportement de prolifération

Country Status (1)

Country Link
WO (1) WO2008110570A1 (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102395673A (zh) * 2009-03-20 2012-03-28 首尔大学校产学协力团 来自脐带血的表达znf281的万能干细胞的分离方法
RU2466680C1 (ru) * 2011-10-03 2012-11-20 Общество С Ограниченной Ответственностью "Витацел" Способ диагностики состояния кожи пациента (варианты)
EP2733200A1 (fr) 2012-11-15 2014-05-21 Biorigen International SA Suppléments de culture cellulaire
WO2015175807A1 (fr) * 2014-05-16 2015-11-19 Mayo Foundation For Medical Education And Research Compositions de milieux de culture cellulaire pour cellules primaires
US10166258B2 (en) 2008-09-16 2019-01-01 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
CN109652361A (zh) * 2017-10-12 2019-04-19 北京弘润天源基因生物技术有限公司 一种人脐静脉血管内皮细胞的原代分离培养及鉴定方法
CN109694843A (zh) * 2017-10-20 2019-04-30 北京弘润天源基因生物技术有限公司 一种优化的人脐静脉血管内皮细胞获取方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092108A1 (fr) * 2001-05-11 2002-11-21 Children's Medical Center Corporation ¨ Procedes relatifs a l'evaluation d'agents antiangiogeniques
WO2004045517A2 (fr) * 2002-11-15 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methode de diagnostic et de traitement de maladie vasculaire
WO2005078073A2 (fr) * 2004-02-09 2005-08-25 Indiana University Research And Technology Corporation Isolement, expansion et utilisation de progeniteurs clonogenes de cellules endotheliales
WO2005120090A2 (fr) * 2004-06-01 2005-12-15 In Motion Investment, Ltd. Techniques in vitro utilisees avec des cellules souches
EP1860196A1 (fr) * 2005-02-23 2007-11-28 Foundation for Biomedical Research and Innovation Procédé d'analyse de la dynamique dans la différentiation des cellules souches endothéliales vasculaires

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092108A1 (fr) * 2001-05-11 2002-11-21 Children's Medical Center Corporation ¨ Procedes relatifs a l'evaluation d'agents antiangiogeniques
WO2004045517A2 (fr) * 2002-11-15 2004-06-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Methode de diagnostic et de traitement de maladie vasculaire
WO2005078073A2 (fr) * 2004-02-09 2005-08-25 Indiana University Research And Technology Corporation Isolement, expansion et utilisation de progeniteurs clonogenes de cellules endotheliales
WO2005120090A2 (fr) * 2004-06-01 2005-12-15 In Motion Investment, Ltd. Techniques in vitro utilisees avec des cellules souches
EP1860196A1 (fr) * 2005-02-23 2007-11-28 Foundation for Biomedical Research and Innovation Procédé d'analyse de la dynamique dans la différentiation des cellules souches endothéliales vasculaires

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
HEESCHEN C ET AL: "Erythropoietin is a Potent Physiologic Stimulus for Endothelial Progenitor Cell Mobilization", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 102, no. 4, 2003, pages 1340 - 1346, XP002993403, ISSN: 0006-4971 *
IMANISHI ET AL: "Sirolimus accelerates senescence of endothelial progenitor cells through telomerase inactivation", ATHEROSCLEROSIS, AMSTERDAM, NL, vol. 189, no. 2, December 2006 (2006-12-01), pages 288 - 296, XP005722975, ISSN: 0021-9150 *
ITO H ET AL: "Endothelial progenitor cells as putative targets for angiostatin", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 59, 1 December 1999 (1999-12-01), pages 5875 - 5877, XP002954634, ISSN: 0008-5472 *
LISELOTT JOHANSSON ET AL: "Platelet lysate: a replacement for fetal bovine serum in animal cell culture?", CYTOTECHNOLOGY, KLUWER ACADEMIC PUBLISHERS, DO, vol. 42, no. 2, 1 June 2003 (2003-06-01), pages 67 - 74, XP019236789, ISSN: 1573-0778 *
MARCHETTI VALENTINA ET AL: "Benfotiamine counteracts glucose toxicity effects on endothelial progenitor cell differentiation via Akt/FoxO signaling.", DIABETES AUG 2006, vol. 55, no. 8, August 2006 (2006-08-01), pages 2231 - 2237, XP002476897, ISSN: 0012-1797 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10166258B2 (en) 2008-09-16 2019-01-01 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
US12324816B2 (en) 2008-09-16 2025-06-10 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
US10925901B2 (en) 2008-09-16 2021-02-23 Mayo Foundation For Medical Education And Research Compositions containing platelet contents
US10584312B2 (en) 2009-03-20 2020-03-10 Snu R&Db Foundation Isolating method for umbilical cord blood-derived pluripotent stem cells expressing ZNF281
CN102395673A (zh) * 2009-03-20 2012-03-28 首尔大学校产学协力团 来自脐带血的表达znf281的万能干细胞的分离方法
RU2466680C1 (ru) * 2011-10-03 2012-11-20 Общество С Ограниченной Ответственностью "Витацел" Способ диагностики состояния кожи пациента (варианты)
US8790890B2 (en) 2011-10-03 2014-07-29 Obshhestvo S Organichennoi Otvetstvennost' Yu “Vitacel” Diagnostic method for connective tissue and its application
EP2733200A1 (fr) 2012-11-15 2014-05-21 Biorigen International SA Suppléments de culture cellulaire
WO2015175807A1 (fr) * 2014-05-16 2015-11-19 Mayo Foundation For Medical Education And Research Compositions de milieux de culture cellulaire pour cellules primaires
AU2021277734B2 (en) * 2014-05-16 2023-08-17 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
US11891620B2 (en) 2014-05-16 2024-02-06 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
EP4328299A3 (fr) * 2014-05-16 2024-05-29 Mayo Foundation for Medical Education and Research Compositions de milieux de culture cellulaire pour cellules primaires
US12258576B2 (en) 2014-05-16 2025-03-25 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
US12371657B2 (en) 2014-05-16 2025-07-29 Mayo Foundation For Medical Education And Research Cell culture media compositions for primary cells
CN109652361A (zh) * 2017-10-12 2019-04-19 北京弘润天源基因生物技术有限公司 一种人脐静脉血管内皮细胞的原代分离培养及鉴定方法
CN109694843A (zh) * 2017-10-20 2019-04-30 北京弘润天源基因生物技术有限公司 一种优化的人脐静脉血管内皮细胞获取方法

Similar Documents

Publication Publication Date Title
Denburg et al. Heterogeneity of human peripheral blood eosinophil-type colonies: evidence for a common basophil-eosinophil progenitor
EP1458854B1 (fr) Compositions cellulaires et procedes de preparation et d'utilisation associes
US12480092B2 (en) Method for preparing mature red blood cells in vitro using peripheral blood
WO2008110570A1 (fr) Procédé pour étudier la prolifération de cellules progénitrices endothéliales et l'influence potentielle de composés sur leur comportement de prolifération
Hegab et al. Isolation and characterization of murine multipotent lung stem cells
EP3613847A1 (fr) Procédé d'isolement de cellules pour la thérapie et la prophylaxie
WO2001021766A9 (fr) Procedes et dispositifs permettant d'obtenir des cellules de lignee non hematopoietique a partir de cellules de progeniteurs hematopoietiques
Bol et al. The maturation state of three types of granulocyte/macrophage progenitor cells from mouse bone marrow
WO2011069121A1 (fr) Cellules souches mésenchymateuses (csm) isolées dans le sang périphérique mobilisé
CN110997904B (zh) 改进造血移植物的方法
EP4079842A1 (fr) Composés à petites molécules pour amplifier des cellules souches hématopoïétiques, et leur combinaison
Donnelly et al. Bioengineered niches that recreate physiological extracellular matrix organisation to support long-term haematopoietic stem cells
KR20050042046A (ko) 조혈 줄기세포의 증식방법
US20130052728A1 (en) Compositions and methods for making and using bone marrow mesenchymal stem cells and erythroid progenitor cells
Kudo et al. Flow cytometry definition of rat mammary epithelial cell populations and their distinct radiation responses
CN103540566A (zh) 用于长期造血种群恢复的方法和组合物
CA2475174A1 (fr) Cellules myosatellites isolees, leur utilisation dans la reparation des tissus musculaires et methode d'isolement desdites cellules
EP2258833B1 (fr) Isolation d'une nouvelle population de cellules souches cardiaques
US9273285B1 (en) Shorter colony-forming cell assay
Herman et al. Stromal factors support the expansion of the whole hemopoietic spectrum from bone marrow CD34+ DR− cells and of some hemopoietic subsets from CD34+ and CD34+ DR+ cells
WO2011150375A2 (fr) Milieu de culture de cellules endothéliales formant colonie
Yim et al. Correlation between the immature characteristics of umbilical cord blood–derived mesenchymal stem cells and engraftment of hematopoietic stem cells in NOD/SCID mice
URASHIMA et al. Umbilical cord blood as a rich source of immature hematopoietic stem cells
Keller et al. Clonal generation of multipotent and unipotent hemopoietic blast cell colonies in vitro
Gottschling et al. Primitive and committed human hematopoietic progenitor cells interact with primary murine neural cells and are induced to undergo self-renewing cell divisions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08717679

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08717679

Country of ref document: EP

Kind code of ref document: A1